Member news

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

Revolutionary network of national scanners accelerates diagnosis and drug development to deliver patient benefit

Discovery Park opened its doors for the East Kent Science Jamboree, hosting a record-breaking 1,500 children from 51 Kent schools for a two-day science spectacular.

Aravax announced the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company’s Oxford, UK site.

Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.

The new site reflects Stratagem’s growth as a forward-thinking IP partner, offering clarity, simplicity and relevance across every stage of the client journey.

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. Symbiotic.blue aims to create smarter, multi-targeted therapeutics to tackle complex diseases.

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months.

A Scottish clinical development company is redefining early stage development, taking years off the time it takes for new life improving treatments to become available to patients. BDD Pharma Ltd – based at BioCity Glasgow, one of two Pioneer Group sites in Scotland – has also developed its own, in-house technologies. One of them - OralogiK™ - is a unique patented drug delivery tablet system that enables drugs to be released inside the body at the optimum time, hours after taking the tablets.

A new residential development in North Cambridge is offering science and technology businesses a ready-made solution to one of the city’s most pressing challenges: housing professional staff within easy reach of major employment hubs.

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.

Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.

PIR International spoke with experienced life science executive, Bob Radie, as part of there BioLeader interview series.

Coulter Partners successfully completed a search assignment for Melt&Marble and is pleased to announce the placement of Tue Hodal as its first Chief Technology Officer (CTO).

Strategic partnership between Medicines Discovery Catapult and the Crick ensures continued national delivery of KQ Labs, a leading accelerator programme for early-stage innovators.

Aravax announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer.

Brainomix presented a series of new studies at the European Stroke Organisation Conference (ESOC) in Helsinki, solidifying the position of its market-leading Brainomix 360 Stroke as the most clinically validated stroke AI imaging solution.

Ikarovec has highlighted the therapeutic potential of its approach in geographic atrophy and wet AMD, with presentations at major ophthalmic and gene therapy conferences.

Medicines Discovery Catapult's Chemical Protein Stability Assay generates vital data to support drug discovery innovators and will enhance Selvita’s screening platform.

Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.